Editor's Corner
Peddling Panaceas
February 2023
Aaron Gerds, MD,
Dr. Aaron Gerds discusses the role of advertising in health care, the challenges it can pose, whether physicians are responsible, and what can be done about the complex relationship going forward.
Online Exclusives
FDA Approves Treatment for R/R AML
March 2023
CAR-T Therapy Granted RMAT Designation R/R LBCL
March 2023
New Health Care Policies in FY 2023
March 2023
OCE Announces FOA for Ultra-Rare Cancer Research
March 2023
NEWS
Advertisement
Most Read Articles
- Reduced Venetoclax Exposure With Azacitidine Appears Feasible in Treatment-Naïve AML
- Co-mutation Patterns Allowed for Updated Risk Stratification of NPM1-Mutated AML
- Frontline Chemo-Free Triplet Yields High Rates of MRD-Negative Complete Remission in MCL
- Intensive Chemotherapy Before alloHCT Does Not Improve Survival in AML
- Dalteparin to Apixaban for Upper Extremity DVT in Cancer Patients
Advertisement
Hydroxyurea Adherence Linked With Better Clinical Outcomes in SCD
February 2023
A retrospective study looked at Texas Medicaid claims data for 1,032 individuals ages 2 to 63. Included individuals had one or more inpatient or two or more outpatient SCD diagnoses and had at least one hydroxyurea prescription.
CAR T-Cell Therapy Outcomes in LBCL Similar in Patients Who Do and Do Not Develop CRS
February 2023
Researchers sought to determine the effect of CRS on survival and whether CRS is correlated with the efficacy of CAR T-cell therapy. The retrospective study included 351 patients 18 years and older with LBCL who underwent apheresis for commercial CAR T-cell therapy between May 2018 and January 2021.
HU May Lower Malaria Incidence in Children With Sickle Cell Anemia
February 2023
In children with sickle cell anemia in Africa, the maximum tolerated dose of hydroxyurea is associated with a lower incidence of malaria. The incidence was found to decline when the absolute neutrophil count was below a certain level.